Chugai Pharmaceutical Co. Ltd.
History
| Year | Detail |
|---|---|
| 1925 | After witnessing the devastation caused by the Great Kanto Earthquake, Juzo Ueno set up a pharmaceutical trading company, Chugai Shinyaku Shokai, with the aim of developing medicines from a global perspective. |
| 1943 | The company was reorganized into a corporation and renamed Chugai Pharmaceutical Co., Ltd. |
| 1951 | The company succeeded in the industrial synthesis of glucuronic acid. Guronsan, a detoxification and liver function-improving agent, attracted attention and was exported to 31 countries, mainly in Europe. |
| 1952 | Chugai developed and launched Japan's first household-use transpiration insecticide made with lindane (γ-BHC). |
| 1969 | The company name changed to Eiko Kasei Co., Ltd. following the merger of Fukushima Kasei Co., Ltd. and Fukuma Kasei Co., Ltd. |
| 2001 | Chugai Pharmaceutical entered into a strategic alliance with Roche, which gave Roche a majority stake in Chugai and made Chugai a member of the Roche Group. |
| 2002 | Established in 1932, Nippon Roche merged with Chugai Shinyaku Shokai to form Chugai. |
| 2005 | Chugai launched Actemra, the first therapeutic antibody developed, which has grown into a product sold in 110 countries globally through the Roche Group's channels. |
| 2019 | The company launched FoundationOne CDx Cancer Genomic Profile, a comprehensive cancer-related genomic profiling system using advanced sequencing. This is expected to improve access to personalized medicine for cancer. |
| 2021 | Chugai received approval from Actemra, a Humanized Anti-Human IL-6 Receptor Monoclonal Antibody used to treat severe COVID-19 in Europe. |
| 2022 | The company introduced MITCHGA, an anti-IL-31 receptor humanized monoclonal antibody, in Japan by Maruho Co., Ltd., for the treatment of itching associated with atopic dermatitis. |
BCC Research Beacon 